Literature DB >> 31842631

Rapid and quantitative detection of urinary Cyfra21-1 using fluorescent nanosphere-based immunochromatographic test strip for diagnosis and prognostic monitoring of bladder cancer.

Qifang Lei1,2,3,4, Linlin Zhao1,5, Shuixian Ye3, Yue Sun1,3, Fangjie Xie5, Hong Zhang5, Fangjian Zhou1,6, Song Wu1,2,3.   

Abstract

Bladder cancer is a common malignant tumour with high recurrence rate. Cytokeratin 19 fragments (Cyfra21-1) in urine has been regarded as a promising biomarker for the prognosis and diagnosis of bladder cancer due to the relevance of its high urinary level to the bladder cancer patients. However, currently detection methods of Cyfra21-1 have their limits, such as complicated steps, limited sensitivity or unsatisfying specificity. In this study, we developed a novel time-resolved fluoroimmuno test strip by using europium chelate microparticle (Eu-CM). Detection was performed in simple steps by carrying drops of sample into the well of the test strip, waiting for 15 min and inserting the strip into a fluorescence strip reader for quantitation. The standard curve equation of the test strip was y = 0.0177x + 0.01 (R2 = .9993). In the analysis of human urine samples (n = 115), it demonstrated a good performance (accuracy: CV < 10%, AUC: 0.989). With the cut-off value of 81 ng/mL, the sensitivity and specificity for bladder cancer were 92.86 and 100%, respectively. In comparison to ELISA and electrochemiluminescence methods, the Eu-CM based time-resolved fluoroimmuno test strip provided a rapid, sensitive and reliable method for monitoring bladder cancer. It may be applied as a non-invasive approach for in point-of-care for bladder cancer detection.

Entities:  

Keywords:  Bladder cancer; Cyfra21-1; time-resolved fluoroimmuno assay; urine

Mesh:

Substances:

Year:  2019        PMID: 31842631     DOI: 10.1080/21691401.2019.1687491

Source DB:  PubMed          Journal:  Artif Cells Nanomed Biotechnol        ISSN: 2169-1401            Impact factor:   5.678


  7 in total

Review 1.  Advances in Diagnosis and Therapy for Bladder Cancer.

Authors:  Xinzi Hu; Guangzhi Li; Song Wu
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

2.  A fluorescent microsphere-based immunochromatographic strip is effective for quantitative fecal blood testing in colorectal cancer screening.

Authors:  Qingbing Wang; Jiwu Wang; Zeru Xiao; Zhiling Shen; Yanjun Wang; Yong Zhang; Tianyuan Pan; Jianan Xiao; Xiyuan Sun
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 3.940

3.  Prognostic significance of pre-treatment serum Cyfra21-1 as a tumor marker in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy.

Authors:  Liang Li; Guangping Liu; Kai Jin; Honglue Lu; Xiang Zhai; Mengqian Zhou; Kai Yue; Yuansheng Duan; Yansheng Wu; Xudong Wang
Journal:  Ann Transl Med       Date:  2020-10

Review 4.  The Use of Upconversion Nanoparticles in Prostate Cancer Photodynamic Therapy.

Authors:  Michał Osuchowski; Filip Osuchowski; Wojciech Latos; Aleksandra Kawczyk-Krupka
Journal:  Life (Basel)       Date:  2021-04-19

5.  Development of a Colloidal Gold Immunochromatographic Strip for Rapid Detection of Cyfra 21-1 in Lymph Node Metastasis of Thyroid Cancer.

Authors:  Lijie Xu; Shuhao Wang; Zhechen Wu; Chengcheng Xu; Xinwei Hu; Haitian Ding; Yanqiang Zhang; Bing Shen; Yehai Liu; Kaile Wu
Journal:  Front Bioeng Biotechnol       Date:  2022-04-12

6.  Lateral Flow Immunoassay Based on Time-Resolved Fluorescence Microspheres for Rapid and Quantitative Screening CA199 in Human Serum.

Authors:  Xueshima Jiao; Tao Peng; Zhanwei Liang; Yalin Hu; Bo Meng; Yang Zhao; Jie Xie; Xiaoyun Gong; You Jiang; Xiang Fang; Xiaoping Yu; Xinhua Dai
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

Review 7.  Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein?

Authors:  Nada Humayun-Zakaria; Douglas G Ward; Roland Arnold; Richard T Bryan
Journal:  Transl Androl Urol       Date:  2021-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.